AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
Log in

NASDAQ:AMPHAmphastar Pharmaceuticals Stock Price, Forecast & News

$18.64
+0.02 (+0.11 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$18.28
Now: $18.64
$18.73
50-Day Range
$15.88
MA: $17.49
$19.18
52-Week Range
$12.32
Now: $18.64
$22.85
Volume329,371 shs
Average Volume281,919 shs
Market Capitalization$861.13 million
P/E Ratio17.75
Dividend YieldN/A
Beta1.11
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products. It offers enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; naloxone for opioid overdose; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; lidocaine jelly, a local anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection for newborn babies; and morphine, atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; lorazepam injection for surgery and medical procedures. In addition, it offers procainamide for documented ventricular arrhythmias; neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy; and isoproterenol hydrochloride injection for mild or transient episodes of heart block, as well as recombinant human and porcine insulins. Further, the company has a pipeline of 20 product candidates in various stages of development for various indications. Its products are used in hospital or urgent care clinical settings, and primarily contracted and distributed through group purchasing organizations and drug wholesalers. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Read More
Amphastar Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.89 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AMPH
CUSIPN/A
Phone909-980-9484

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$322.36 million
Cash Flow$0.76 per share
Book Value$9.16 per share

Profitability

Net Income$48.94 million

Miscellaneous

Employees2,027
Market Cap$861.13 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive AMPH News and Ratings via Email

Sign-up to receive the latest news and ratings for AMPH and its competitors with MarketBeat's FREE daily newsletter.

Amphastar Pharmaceuticals (NASDAQ:AMPH) Frequently Asked Questions

How has Amphastar Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Amphastar Pharmaceuticals' stock was trading at $15.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AMPH stock has increased by 21.8% and is now trading at $18.64. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Amphastar Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amphastar Pharmaceuticals.

When is Amphastar Pharmaceuticals' next earnings date?

Amphastar Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Amphastar Pharmaceuticals.

How were Amphastar Pharmaceuticals' earnings last quarter?

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) issued its quarterly earnings data on Thursday, May, 7th. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.09 by $0.08. The company earned $84.69 million during the quarter, compared to analyst estimates of $81.80 million. Amphastar Pharmaceuticals had a net margin of 15.90% and a return on equity of 4.99%. View Amphastar Pharmaceuticals' earnings history.

What price target have analysts set for AMPH?

4 brokers have issued 12 month target prices for Amphastar Pharmaceuticals' stock. Their forecasts range from $21.00 to $29.00. On average, they expect Amphastar Pharmaceuticals' share price to reach $24.33 in the next year. This suggests a possible upside of 30.5% from the stock's current price. View analysts' price targets for Amphastar Pharmaceuticals.

Has Amphastar Pharmaceuticals been receiving favorable news coverage?

News headlines about AMPH stock have trended extremely negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Amphastar Pharmaceuticals earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutAmphastar Pharmaceuticals.

Are investors shorting Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 3,240,000 shares, an increase of 8.4% from the April 30th total of 2,990,000 shares. Based on an average daily volume of 271,000 shares, the short-interest ratio is currently 12.0 days. Approximately 9.3% of the shares of the stock are sold short. View Amphastar Pharmaceuticals' Current Options Chain.

Who are some of Amphastar Pharmaceuticals' key competitors?

What other stocks do shareholders of Amphastar Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), AbbVie (ABBV), CNX Resources (CNX), Exelixis (EXEL), Advanced Micro Devices (AMD), NVIDIA (NVDA), Abbott Laboratories (ABT) and Allergan (AGN).

Who are Amphastar Pharmaceuticals' key executives?

Amphastar Pharmaceuticals' management team includes the following people:
  • Dr. Ziping Luo, Chairman, Chief Scientist & COO (Age 69)
  • Dr. Yongfeng Zhang, CEO, Chief Science Officer & Director (Age 72)
  • Mr. Jason B. Shandell, Pres, Gen. Counsel & Director (Age 45)
  • Mr. William J. Peters, CFO, Treasurer & Sr. VP of Fin. (Age 51)
  • Mr. Jacob Liawatidewi M.B.A., Sr. VP of Corp. Admin. Center, Sales and Marketing & Corp. Sec. (Age 45)

What is Amphastar Pharmaceuticals' stock symbol?

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

Who are Amphastar Pharmaceuticals' major shareholders?

Amphastar Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.42%), Federated Hermes Inc. (5.62%), State Street Corp (2.59%), Invesco Ltd. (1.61%), Geode Capital Management LLC (1.16%) and Bank of New York Mellon Corp (0.81%). Company insiders that own Amphastar Pharmaceuticals stock include Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Physics & Chemistry La Applied, Richard K Prins, Richard Koo, Rong Zhou, William J Peters and Yakob Liawatidewi. View institutional ownership trends for Amphastar Pharmaceuticals.

Which major investors are selling Amphastar Pharmaceuticals stock?

AMPH stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Wells Fargo & Company MN, Squarepoint Ops LLC, First Trust Advisors LP, Rothschild & Co. Asset Management US Inc., UBS Group AG, Parametric Portfolio Associates LLC, and Rhumbline Advisers. Company insiders that have sold Amphastar Pharmaceuticals company stock in the last year include Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Richard Koo, William J Peters, and Yakob Liawatidewi. View insider buying and selling activity for Amphastar Pharmaceuticals.

Which major investors are buying Amphastar Pharmaceuticals stock?

AMPH stock was purchased by a variety of institutional investors in the last quarter, including Federated Hermes Inc., State Street Corp, BlackRock Inc., Morgan Stanley, Morgan Stanley, AQR Capital Management LLC, Eagle Asset Management Inc., and Geode Capital Management LLC. View insider buying and selling activity for Amphastar Pharmaceuticals.

How do I buy shares of Amphastar Pharmaceuticals?

Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amphastar Pharmaceuticals' stock price today?

One share of AMPH stock can currently be purchased for approximately $18.64.

How big of a company is Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals has a market capitalization of $861.13 million and generates $322.36 million in revenue each year. The company earns $48.94 million in net income (profit) each year or $0.36 on an earnings per share basis. Amphastar Pharmaceuticals employs 2,027 workers across the globe.

What is Amphastar Pharmaceuticals' official website?

The official website for Amphastar Pharmaceuticals is www.amphastar.com.

How can I contact Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at 909-980-9484 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.